AI Article Synopsis
- The study involved 98 patients with Candida vulvovaginitis (CVV), classifying them into three clinical forms: acute (26 patients), subacute (23 patients), and remission (49 patients).
- The clinical diagnosis was confirmed in 87.7% of cases through cytology or culture before treatment, and 4% cytologically in remission, with 20 patients showing positive cultures.
- The findings indicated that in acute CVV, Candida mainly presented in the budding phase (84.4%), while the cytological method proved to be more cost-effective and efficient compared to cultural methods.
Article Abstract
98 patients with Candida vulvovaginitis (CVV) were examined clinically, cytologically and culturally. Three clinical forms of CVV were distinguished: acute and subacute (26 and 23 patients, respectively)--before treatment, and remission (49 patients)--after treatment. The clinical diagnosis of CVV before the treatment was confirmed cytologically and/or in cultures (87.7%), in remission cytologically (4%), by cultures (20 patients). Candida in the phase of budding and pseudomycelium were prevalent in acute CVV (84.4%). In a subacute form Candida occurred in 30.3%, while in the remaining cases blastospores were observed. Significant correlation between the intensity of Candida colonies growth and phase of development on the mucous membrane was not found. Compared to the cultural method, the cytological technique is more cost effective, faster and simpler.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Candida albicans migrates itself from the vagina to the uterus and ovaries in estrogenized mice.
Braz J Microbiol
January 2025
Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil.
Vulvovaginal candidiasis (VVC) represents the second cause of vaginal infections in childbearing-age women. It mainly affects the vulva and vagina; however, other organs can be compromised, with consequences that are not well known yet. To evaluate the ability of Candida albicans, inoculated into the vaginal lumen of mice, to migrate to the uterus and ovaries.
View Article and Find Full Text PDFVaginal colonization and vertical transmission of Candida species: prevalence and associated factors among pregnant women and their neonates at public health facilities of Northeast Ethiopia.
BMC Pregnancy Childbirth
January 2025
Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Background: Vaginal colonization by Candida can lead to vulvovaginal candidiasis, which is the second most prevalent vaginal condition globally. It is frequently associated with sepsis and adverse neonatal outcomes in pregnant women. This issue is worsening in Sub-Saharan Africa, including Ethiopia.
View Article and Find Full Text PDFDistribution and antifungal susceptibility of species causing vulvovaginal candidiasis and urinary tract infection in Medlatec healthcare system, Ha Noi city, Vietnam in 2023.
Ther Adv Infect Dis
January 2025
Department of Medical Parasitology, Military Medical University, No. 160 Phunghung Road, Hadong District, Hanoi 100000, Vietnam.
Background: Vulvovaginal candidiasis and urinary tract infections caused by are common diseases. While the most common causative agent is , other species, such as non-, can also be responsible. Susceptibility to antifungal drugs varies among species, but there is very limited information available from Vietnam.
View Article and Find Full Text PDFVaginal Transcriptional Signatures of the Neutrophil-Driven Immune Response Correlate With Clinical Severity During Recurrent Vulvovaginal Candidiasis.
Am J Reprod Immunol
January 2025
Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Department of Infectious Diseases, Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Problem: Recurrent vulvovaginal candidiasis (RVVC) affects 5%-10% of all women, negatively impacting their reproductive health and quality of life. Herein, we investigated the molecular effects of RVVC on the vaginal mucosa of otherwise healthy women.
Method Of Study: Gene expression analysis was performed on vaginal tissue biopsies from women with RVVC, including those with a current episode of vulvovaginal candidiasis (VVC, n = 19) and women between infections (culture negative RVVC [CNR], n = 8); women asymptomatically colonized with Candida albicans (asymptomatic [AS], n = 7); and healthy controls (n = 18).
Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.
Pharmaceutics
December 2024
Femicare, Clinical Research for Women, 3300 Tienen, Belgium.
Currently, the rising prevalence of resistant species, particularly , as well as non-albicans isolates such as and , represent challenges in their management. In this review, we aimed to explore the current management of fluconazole-resistant vulvovaginal candidiasis (FRVVC). Identified studies focused on alternative antifungal therapies, including boric acid, nystatin, and newer agents like oteseconazole and ibrexafungerp.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!